Published in Cell on October 06, 1989
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A (1996) 9.15
Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol (1993) 6.11
The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions. J Virol (1992) 5.30
Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol (1992) 4.72
Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol (1995) 4.45
Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J Virol (2007) 3.93
Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants. J Virol (1993) 3.75
The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci U S A (1994) 3.65
Role of two forms of hepatitis delta virus antigen: evidence for a mechanism of self-limiting genome replication. J Virol (1990) 3.57
A mutation in the human immunodeficiency virus type 1 transmembrane glycoprotein gp41 dominantly interferes with fusion and infectivity. Proc Natl Acad Sci U S A (1992) 3.01
Rev and the fate of pre-mRNA in the nucleus: implications for the regulation of RNA processing in eukaryotes. Mol Cell Biol (1993) 2.79
Human immunodeficiency virus vectors for inducible expression of foreign genes. J Virol (1992) 2.70
Oligomerization and RNA binding domains of the type 1 human immunodeficiency virus Rev protein: a dual function for an arginine-rich binding motif. Proc Natl Acad Sci U S A (1991) 2.66
Specificity and sequence requirements for interactions between various retroviral Gag proteins. J Virol (1994) 2.50
A block to human immunodeficiency virus type 1 assembly in murine cells. J Virol (2000) 2.47
A human cell factor is essential for HIV-1 Rev action. EMBO J (1990) 2.43
Complementation of murine cells for human immunodeficiency virus envelope/CD4-mediated fusion in human/murine heterokaryons. J Virol (1992) 2.15
Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells. J Virol (1994) 1.99
Inhibition of human immunodeficiency virus type 1 expression by a hairpin ribozyme. Proc Natl Acad Sci U S A (1992) 1.96
A multistep, ATP-dependent pathway for assembly of human immunodeficiency virus capsids in a cell-free system. J Cell Biol (1997) 1.89
Role for human immunodeficiency virus type 1 membrane cholesterol in viral internalization. J Virol (2002) 1.81
Genetic assay for multimerization of retroviral gag polyproteins. J Virol (1992) 1.74
Efficient replication of human immunodeficiency virus type 1 requires a threshold level of Rev: potential implications for latency. J Virol (1992) 1.74
Characterization of deletion mutations in the capsid region of human immunodeficiency virus type 1 that affect particle formation and Gag-Pol precursor incorporation. J Virol (1995) 1.73
In vivo infection of sheep by bovine leukemia virus mutants. J Virol (1993) 1.69
A transdominant tat mutant that inhibits tat-induced gene expression from the human immunodeficiency virus long terminal repeat. Proc Natl Acad Sci U S A (1990) 1.55
In vitro selection of RNAs that bind to the human immunodeficiency virus type-1 gag polyprotein. Nucleic Acids Res (1997) 1.53
The Nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix. J Virol (1997) 1.52
Incorporation of human immunodeficiency virus type 1 Gag proteins into murine leukemia virus virions. J Virol (1993) 1.52
Characterization of human immunodeficiency virus type 1 Pr55gag membrane association in a cell-free system: requirement for a C-terminal domain. Proc Natl Acad Sci U S A (1994) 1.49
Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease. Proc Natl Acad Sci U S A (1990) 1.46
Inhibition of human immunodeficiency virus type 1 replication in human T cells by retroviral-mediated gene transfer of a dominant-negative Rev trans-activator. Proc Natl Acad Sci U S A (1992) 1.45
Sequence requirements for encapsidation of deletion mutants and chimeras of human immunodeficiency virus type 1 Gag precursor into retrovirus-like particles. J Virol (1995) 1.44
Spleen necrosis virus gag polyprotein is necessary for particle assembly and release but not for proteolytic processing. J Virol (1990) 1.42
Matrix protein of Akv murine leukemia virus: genetic mapping of regions essential for particle formation. J Virol (1992) 1.37
A fusion-defective mutant of the vesicular stomatitis virus glycoprotein. J Virol (1990) 1.37
Assembly-defective point mutants of the human immunodeficiency virus type 1 Gag precursor phenotypically expressed in recombinant baculovirus-infected cells. J Virol (1993) 1.37
The blocks to human immunodeficiency virus type 1 Tat and Rev functions in mouse cell lines are independent. J Virol (1993) 1.34
Late viral interference induced by transdominant Gag of an endogenous retrovirus. Proc Natl Acad Sci U S A (2004) 1.34
Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc Natl Acad Sci U S A (1996) 1.30
A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle. J Virol (2009) 1.30
Transdominant repressors for human T-cell leukemia virus type I rex and human immunodeficiency virus type 1 rev function. J Virol (1991) 1.28
A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. Proc Natl Acad Sci U S A (1996) 1.27
Mutational analysis of the hydrophobic tail of the human immunodeficiency virus type 1 p6(Gag) protein produces a mutant that fails to package its envelope protein. J Virol (1999) 1.25
Human immunodeficiency virus type 1 MA deletion mutants expressed in baculovirus-infected cells: cis and trans effects on the Gag precursor assembly pathway. J Virol (1995) 1.24
Specific inhibitor of human immunodeficiency virus proteinase prevents the cytotoxic effects of a single-chain proteinase dimer and restores particle formation. J Virol (1992) 1.21
Characterization of the gag/fusion protein encoded by the defective Duplan retrovirus inducing murine acquired immunodeficiency syndrome. J Virol (1990) 1.20
Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc Natl Acad Sci U S A (1998) 1.17
Identification and analysis of antisense RNA target regions of the human immunodeficiency virus type 1. Nucleic Acids Res (1991) 1.14
A molecular determinant of human immunodeficiency virus particle assembly located in matrix antigen p17. J Virol (1995) 1.13
A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1993) 1.13
Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T cells. Proc Natl Acad Sci U S A (1994) 1.12
Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation. Proc Natl Acad Sci U S A (1995) 1.10
Selective killing of CD4+ cells harboring a human immunodeficiency virus-inducible suicide gene prevents viral spread in an infected cell population. Proc Natl Acad Sci U S A (1992) 1.09
Transdominant human T-cell lymphotropic virus type I TAX1 mutant that fails to localize to the nucleus. J Virol (1991) 1.04
Moloney murine leukemia virus integrase protein augments viral DNA synthesis in infected cells. J Virol (2001) 1.03
Tat- and Rev-directed antisense RNA expression inhibits and abolishes replication of human immunodeficiency virus type 1: a temporal analysis. J Virol (1992) 1.02
Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense, or polymeric trans-activation response element constructs. Proc Natl Acad Sci U S A (1995) 1.00
Combined intra- and extracellular immunization against human immunodeficiency virus type 1 infection with a human anti-gp120 antibody. Proc Natl Acad Sci U S A (1994) 0.99
Blockade of human immunodeficiency virus type 1 production in CD4+ T cells by an intracellular CD4 expressed under control of the viral long terminal repeat. Proc Natl Acad Sci U S A (1993) 0.98
Engineering human immunodeficiency virus 1 protease heterodimers as macromolecular inhibitors of viral maturation. Proc Natl Acad Sci U S A (1996) 0.97
Transdominant activity of human immunodeficiency virus type 1 Vpr with a mutation at residue R73. J Virol (2000) 0.97
Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr-containing protease cleavage site residues on virus replication. Proc Natl Acad Sci U S A (1997) 0.92
Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag. J Virol (1996) 0.91
Gene therapy for infectious diseases. Clin Microbiol Rev (1998) 0.91
trans-dominant interference with virus infection at two different stages by a mutant envelope protein of Friend murine leukemia virus. J Virol (1993) 0.89
A Rev-inducible mutant gag gene stably transferred into T lymphocytes: an approach to gene therapy against human immunodeficiency virus type 1 infection. Proc Natl Acad Sci U S A (1994) 0.88
Nef from human immunodeficiency virus type 1(F12) inhibits viral production and infectivity. J Virol (2001) 0.88
A nuclear export signal within the structural Gag protein is required for prototype foamy virus replication. Retrovirology (2011) 0.86
Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 replication. J Virol (1998) 0.86
Inhibition of human immunodeficiency virus type 1 replication is enhanced by a combination of transdominant Tat and Rev proteins. J Virol (1996) 0.86
Transdominant inhibition of wild-type human immunodeficiency virus type 2 replication by an envelope deletion mutant. J Virol (1993) 0.85
Differential effects of human cytomegalovirus on integrated and unintegrated human immunodeficiency virus sequences. J Virol (1995) 0.85
Homologous interference resulting from the presence of defective particles of human immunodeficiency virus type 1. J Virol (1995) 0.84
Targeting tat inhibitors in the assembly of human immunodeficiency virus type 1 transcription complexes. J Virol (2008) 0.83
A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells. Hum Gene Ther (2013) 0.82
Intracellular expression of RNA transcripts complementary to the human immunodeficiency virus type 1 gag gene inhibits viral replication in human CD4+ lymphocytes. J Virol (1996) 0.81
Engineering T Cells to Functionally Cure HIV-1 Infection. Mol Ther (2015) 0.81
Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses. Proc Natl Acad Sci U S A (1994) 0.81
Efficient production of HIV-1 virus-like particles from a mammalian expression vector requires the N-terminal capsid domain. PLoS One (2011) 0.80
Crystal structure of an antiviral ankyrin targeting the HIV-1 capsid and molecular modeling of the ankyrin-capsid complex. J Comput Aided Mol Des (2014) 0.79
Molecular determinants of the ratio of inert to infectious virus particles. Prog Mol Biol Transl Sci (2014) 0.79
A second-site suppressor significantly improves the defective phenotype imposed by mutation of an aromatic residue in the N-terminal domain of the HIV-1 capsid protein. Virology (2006) 0.79
Bone Marrow Gene Therapy for HIV/AIDS. Viruses (2015) 0.79
Novel macromolecular inhibitors of human immunodeficiency virus-1 protease. Protein Eng Des Sel (2008) 0.78
Targeting the HIV entry, assembly and release pathways for anti-HIV gene therapy. Virology (2011) 0.78
Gene therapy for HIV infections: Intracellular immunization. Can J Infect Dis (1999) 0.77
Dominant-negative proteins in herpesviruses - from assigning gene function to intracellular immunization. Viruses (2009) 0.77
Is gene therapy a good therapeutic approach for HIV-positive patients? Genet Vaccines Ther (2007) 0.76
Interaction between the dominant negative mutant and the wild-type envelope proteins of Friend murine leukemia virus. J Virol (1994) 0.76
My Cousin, My Enemy: quasispecies suppression of drug resistance. Curr Opin Virol (2016) 0.76
Bridging the gap: a Canadian perspective on translational kidney research. Can J Kidney Health Dis (2014) 0.75
Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell (1983) 25.46
Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A (1993) 22.33
A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins. Cell (1989) 21.54
Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell (1986) 20.08
RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature (1970) 19.38
An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature (1987) 19.23
I kappa B: a specific inhibitor of the NF-kappa B transcription factor. Science (1988) 16.40
Immunoglobulin gene transcription is activated by downstream sequence elements. Cell (1983) 15.53
Inducibility of kappa immunoglobulin enhancer-binding protein Nf-kappa B by a posttranslational mechanism. Cell (1986) 15.30
A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. Nature (1986) 14.34
An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science (1996) 13.87
Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase. J Virol (1981) 13.11
NF-kappa B: ten years after. Cell (1996) 12.80
HTLV-III expression and production involve complex regulation at the levels of splicing and translation of viral RNA. Cell (1986) 12.74
Cloned poliovirus complementary DNA is infectious in mammalian cells. Science (1981) 12.50
Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci U S A (1981) 12.00
Ribonucleic acid synthesis of vesicular stomatitis virus, II. An RNA polymerase in the virion. Proc Natl Acad Sci U S A (1970) 11.83
Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. Cell (1988) 11.62
NF-kappa B: a pleiotropic mediator of inducible and tissue-specific gene control. Cell (1989) 11.19
The "initiator" as a transcription control element. Cell (1989) 11.13
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science (1990) 10.59
Polypeptide cleavages in the formation of poliovirus proteins. Proc Natl Acad Sci U S A (1968) 10.43
Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature (1995) 10.36
Changes in thymic function with age and during the treatment of HIV infection. Nature (1998) 10.27
The V(D)J recombination activating gene, RAG-1. Cell (1989) 9.79
Heavy chain variable region contribution to the NPb family of antibodies: somatic mutation evident in a gamma 2a variable region. Cell (1981) 9.54
Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol (1989) 9.37
RAG-1 and RAG-2, adjacent genes that synergistically activate V(D)J recombination. Science (1990) 9.33
Activation in vitro of NF-kappa B by phosphorylation of its inhibitor I kappa B. Nature (1990) 9.31
Further evidence on the formation of poliovirus proteins. J Mol Biol (1970) 9.29
Cloning of the p50 DNA binding subunit of NF-kappa B: homology to rel and dorsal. Cell (1990) 9.24
A detailed model of reverse transcription and tests of crucial aspects. Cell (1979) 8.93
The trans-activator gene of HTLV-III is essential for virus replication. Nature (1986) 8.65
A lymphoid-specific protein binding to the octamer motif of immunoglobulin genes. Nature (1986) 8.64
Joining of immunoglobulin heavy chain gene segments: implications from a chromosome with evidence of three D-JH fusions. Proc Natl Acad Sci U S A (1982) 8.53
Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature (1986) 8.36
Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements. Cell (1985) 8.16
Covalent linkage of a protein to a defined nucleotide sequence at the 5'-terminus of virion and replicative intermediate RNAs of poliovirus. Proc Natl Acad Sci U S A (1977) 8.12
Identification of a ten-amino acid proline-rich SH3 binding site. Science (1993) 8.05
Protein-binding sites in Ig gene enhancers determine transcriptional activity and inducibility. Science (1987) 7.63
Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell (1995) 7.55
ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev (2000) 7.28
Defective viral particles and viral disease processes. Nature (1970) 7.24
Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell (1988) 7.01
HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature (1998) 6.94
A functional ribonucleoprotein complex forms around the 5' end of poliovirus RNA. Cell (1990) 6.85
Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood (1998) 6.81
The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity (1999) 6.80
5'-terminal structure of poliovirus polyribosomal RNA is pUp. Proc Natl Acad Sci U S A (1976) 6.78
Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine. Nature (1980) 6.76
Structure of a cloned circular Moloney murine leukemia virus DNA molecule containing an inverted segment: implications for retrovirus integration. Proc Natl Acad Sci U S A (1980) 6.73
Gene conversion: some implications for immunoglobulin genes. Cell (1981) 6.70
Ordered rearrangement of immunoglobulin heavy chain variable region segments. EMBO J (1984) 6.67
DNA binding and I kappa B inhibition of the cloned p65 subunit of NF-kappa B, a rel-related polypeptide. Cell (1991) 6.63
Morphogenesis of poliovirus. I. Association of the viral RNA with coat protein. J Mol Biol (1968) 6.58
Activation of interleukin-6 gene expression through the NF-kappa B transcription factor. Mol Cell Biol (1990) 6.57
Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo. Cell (1991) 6.48
Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells. Proc Natl Acad Sci U S A (1978) 6.38
Modular binding domains in signal transduction proteins. Cell (1995) 6.34
Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev (1996) 6.32
Organization and reorganization of immunoglobulin genes in A-MULV-transformed cells: rearrangement of heavy but not light chain genes. Cell (1981) 6.31
Standardized and simplified nomenclature for proteins common to all retroviruses. J Virol (1988) 6.31
Poliovirus RNA synthesis utilizes an RNP complex formed around the 5'-end of viral RNA. EMBO J (1993) 6.29
The POU domain: a large conserved region in the mammalian pit-1, oct-1, oct-2, and Caenorhabditis elegans unc-86 gene products. Genes Dev (1988) 6.23
RNA metabolism of murine leukemia virus: detection of virus-specific RNA sequences in infected and uninfected cells and identification of virus-specific messenger RNA. J Mol Biol (1973) 6.19
RNA-directed DNA synthesis and RNA tumor viruses. Adv Virus Res (1972) 6.11
Immunoglobulin synthesis by lymphoid cells transformed in vitro by Abelson murine leukemia virus. Cell (1979) 6.03
Ribonucleic acid synthesis of vesicular stomatitis virus. 3. Multiple complementary messenger RNA molecules. Virology (1970) 5.99
Aspects of the synthesis of poliovirus RNA and the formation of virus particles. Virology (1966) 5.85
In vitro synthesis of a 9 kbp terminally redundant DNA carrying the infectivity of Moloney murine leukemia virus. Cell (1979) 5.78
Preferential utilization of the most JH-proximal VH gene segments in pre-B-cell lines. Nature (1984) 5.75
Ribonucleic acid synthesis of vesicular stomatitis virus. I. Species of ribonucleic acid found in Chinese hamster ovary cells infected with plaque-forming and defective particles. J Virol (1969) 5.73
High frequency of aberrant expression of Moloney murine leukemia virus in clonal infections. Cell (1978) 5.72
Structure of the Abelson murine leukemia virus genome and the homologous cellular gene: studies with cloned viral DNA. Cell (1980) 5.68
A 65-kappaD subunit of active NF-kappaB is required for inhibition of NF-kappaB by I kappaB. Genes Dev (1989) 5.61
Synthesis of secreted and membrane-bound immunoglobulin mu heavy chains is directed by mRNAs that differ at their 3' ends. Cell (1980) 5.59
Primer requirement and template specificity of the DNA polymerase of RNA tumor viruses. Proc Natl Acad Sci U S A (1971) 5.55
The involvement of NF-kappa B in beta-interferon gene regulation reveals its role as widely inducible mediator of signal transduction. Cell (1989) 5.50
A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell (1990) 5.39
The mechanism of RNA recombination in poliovirus. Cell (1986) 5.35
Translation of MuLV and MSV RNAs in nuclease-treated reticulocyte extracts: enhancement of the gag-pol polypeptide with yeast suppressor tRNA. Cell (1978) 5.31
The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med (1994) 5.22
Varying the position of a retrovirus packaging sequence results in the encapsidation of both unspliced and spliced RNAs. J Virol (1985) 5.21
A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus. J Exp Med (1976) 5.13
Poliovirus mutant that does not selectively inhibit host cell protein synthesis. Mol Cell Biol (1985) 4.94
An inhibitory domain of E12 transcription factor prevents DNA binding in E12 homodimers but not in E12 heterodimers. Cell (1991) 4.80
Transcriptional activation by Sp1 as directed through TATA or initiator: specific requirement for mammalian transcription factor IID. Proc Natl Acad Sci U S A (1990) 4.79
Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med (1996) 4.79
Ordered transcription of RNA tumor virus genomes. J Mol Biol (1976) 4.78
Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell (1990) 4.78
Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I. Cell (1987) 4.76
The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc Natl Acad Sci U S A (1991) 4.66
Inhibition of translation by poliovirus: inactivation of a specific initiation factor. Proc Natl Acad Sci U S A (1978) 4.59
Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature (1990) 4.59
Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho. Science (1992) 4.57
Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides. Nature (1992) 4.46
Tumor viruses: 1974. Cold Spring Harb Symp Quant Biol (1975) 4.44
Retracted Uncoupling IL-2 signals that regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity (1999) 4.42
Id proteins Id1 and Id2 selectively inhibit DNA binding by one class of helix-loop-helix proteins. Mol Cell Biol (1991) 4.42